Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKL9X7)

Drug Name

[3H]bag-2 Drug Info

Synonyms

2-[4-[2-[5-(Cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid; Bag-2; CHEMBL1084942; 2-[4-[2-[5-(cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid; GTPL6189; SCHEMBL6982673; GTPL8506; BDBM50313741; 4''-(2-(5-(cyclopentylmethyl)-1H-imidazol-2-yl)ethyl)biphenyl-2-carboxylic acid; bag-2

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 25025654
TTD Drug ID: DMKL9X7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bombesin receptor (BS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Demobesin	DMPXLMB	Breast cancer	2C60-2C65	Phase 1	[2]
BAY-86-7548	DM195JA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
kuwanon H	DMVQDNR	Discovery agent	N.A.	Investigative	[4]
bombesin	DMDFQ0Y	Discovery agent	N.A.	Investigative	[5]
PD 168368	DMFNQEA	Discovery agent	N.A.	Investigative	[6]
MK-5046	DMS7C6R	Discovery agent	N.A.	Investigative	[7]
bantag-1	DM4OT8M	Discovery agent	N.A.	Investigative	[8]
ranatensin	DMI7NAF	Discovery agent	N.A.	Investigative	[9]
PD 176252	DM7AY6K	Discovery agent	N.A.	Investigative	[6]
[(N4-Bzdig)0]BB(7-14)	DMD4BSJ	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bombesin receptor (BS)	TTHYDUM	NMBR_HUMAN; GRPR_HUMAN; BRS3_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab. 2010 Feb 3;11(2):101-12.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38).
3	Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72.
4	Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
5	Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
6	Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides. 2009 Aug;30(8):1473-86.
7	Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. J Pharmacol Exp Ther. 2011 Feb;336(2):356-64.
8	Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.
9	Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R). Biochemistry. 1999 Jun 1;38(22):7307-20.
10	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.